Study in Patients With Osteoporosis and Fragility Fractures to Estimate the Extent and Impact of Delayed Administration of Anti-fracture Therapy
NCT07512453 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 8000
Last updated 2026-04-06
Summary
Osteoporosis (OP) and fragility fractures are a significant problem that leads to morbidity, mortality, and high costs for the National Health System. The treatment of fragility fractures includes numerous anti-resorptive and anabolic drugs, and its goal is the secondary prevention of new fractures. It is well known that the risk of a new fracture following a fracture event is highest in the months immediately following the first fracture. However, recent data clearly show a dramatic global delay in the administration of anti-osteoporotic therapy following a fragility fracture. It has been estimated that in Italy, 71% of patients with fragility fractures eligible for anti-fracture treatment did not receive timely treatment (a problem defined as a "treatment gap"), and that in 2034, the incidence of new fragility fractures will increase compared to 2019 \[1\]. However, there is a lack of real-life Italian data on the extent of the treatment gap in osteoporotic patients with fragility fractures and its impact in terms of the incidence of subsequent fragility fractures: this study therefore aims to fill this gap by collecting data from a large population of patients attending several centers throughout the country.
Conditions
Sponsors & Collaborators
-
Azienda Ospedaliero, Universitaria Pisana
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-01
- Primary Completion
- 2027-03-31
- Completion
- 2029-03-31
Countries
- Italy
Study Locations
More Related Trials
-
Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
NCT02435147 ·Status: COMPLETED
-
Evaluation of a Decision Analysis Model in the DASH-Osteo Decision Aid.
NCT07120854 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis
NCT00680953 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures
NCT06864130 ·Status: RECRUITING ·Phase: PHASE4
-
A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial)
NCT01801397 ·Status: UNKNOWN ·Phase: PHASE3
-
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
NCT07242612 ·Status: RECRUITING ·Phase: NA
-
Role of Strontium Ranelate in Proximal Femur Fragility Fractures.
NCT05712616 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of PTH(1-34) Treatment on Fracture Healing in Vivo
NCT00741182 ·Status: WITHDRAWN ·Phase: PHASE2
-
Randomized, Open, Parallel, Active Controlled Study on Fracture Prevention in Antiosteoporosis Treatment (OF Study)
NCT00165607 ·Status: COMPLETED ·Phase: PHASE4
-
Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease
NCT06421597 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Effects of Denosumab Therapy for Japanese
NCT02491515 ·Status: UNKNOWN
-
Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis
NCT00532337 ·Status: COMPLETED ·Phase: PHASE2
-
Intervention Study of Drugs in Patients Osteopenia and Osteoporosis
NCT04719572 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI
NCT01140321 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Low Bone Density in Cystic Fibrosis.
NCT01812551 ·Status: COMPLETED ·Phase: PHASE3
-
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
NCT01153425 ·Status: COMPLETED ·Phase: PHASE4
-
PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)
NCT00515593 ·Status: COMPLETED
-
STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)
NCT00583518 ·Status: COMPLETED ·Phase: PHASE4
-
Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
NCT00136058 ·Status: COMPLETED ·Phase: PHASE3
-
Bisphosphonates for Prevention of Post-Denosumab Bone Loss
NCT03396315 ·Status: COMPLETED ·Phase: PHASE2
-
Dental Care and Initiation of Anti-osteoporotic Therapy
NCT05719818 ·Status: COMPLETED
-
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
NCT02732210 ·Status: COMPLETED
-
MAGnesium Effect With ANtiosteoporotic Drugs
NCT05328154 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
NCT04704947 ·Status: RECRUITING ·Phase: PHASE3
-
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
NCT06938152 ·Status: RECRUITING ·Phase: PHASE4